Leukemia
Conditions
Keywords
childhood myelodysplastic syndromes, childhood acute myeloid leukemia/other myeloid malignancies, childhood acute megakaryocytic leukemia (M7)
Brief summary
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies DNA samples from patients with Down syndrome and acute myeloid leukemia treated on COG-AAML0431 clinical trial.
Detailed description
OBJECTIVES: * To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in patients with Down syndrome through whole-genome sequencing. OUTLINE: This is a multicenter study. Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene mutation, and microarray analysis.
Interventions
GENETICgene mapping
GENETICmicroarray analysis
GENETICmutation analysis
GENETICnucleic acid sequencing
OTHERlaboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
Children's Oncology Group
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 3 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) * Clinical samples from patients enrolled on the Children's Oncology Group (COG) AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell Bank * Diagnostic blast samples and matched remission samples PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of unique mutations through whole-genome sequencing | — |
Outcome results
None listed